ArticleFrontiers in immunology2026
Transcutaneous auricular vagus nerve stimulation attenuates depressive-like behaviors via enhancing neuroplasticity and regulating the ALK5/Smad2/3/Gadd45β signaling pathway in rats with post-stroke depression.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Post-stroke depression (PSD) adversely affects neurological functional recovery in patients. Transcutaneous auricular vagus nerve stimulation (ta-VNS) has demonstrated antidepressant potential. As the receptor ALK5 may regulate neuroplasticity by modulating the Smad2/3 and Gadd45β signaling pathways, we hypothesized that ta-VNS alleviates PSD by activating this pathway. This study aimed to evaluate the therapeutic effects of ta-VNS on a PSD rat model and to investigate the involvement of the ALK5/Smad2/3/Gadd45β signaling pathway in mediating these effects. Methods: A PSD rat model was established by combining middle cerebral artery occlusion (MCAO) with chronic unpredictable mild stress (CUMS). To investigate the underlying mechanisms, ALK5 expression was knocked down in the right prefrontal cortex (PFC) via AAV-shALK5 injection, followed by a 14-day ta-VNS treatment. Depression-like behaviors were evaluated using the sucrose preference, forced swimming, and open-field tests. Neuroprotection was assessed through hematoxylin-eosin, Nissl, and TUNEL staining. Neurotransmitter expression was measured by enzyme-linked immunosorbent assay (ELISA). Neurogenesis, along with axonal, dendritic, and synaptic plasticity, was assessed by immunostaining and Western blot analysis of DCX, Nestin, NF-200, GAP-43, MAP-2, and PSD95, SYN. Additionally, dendritic morphology was visualized by Golgi-Cox staining, and in addition, synaptic ultrastructure was characterized using transmission electron microscopy. Protein levels of the ALK5/Smad2/3/Gadd45β pathway were analyzed by Western blot. Results: Ta-VNS treatment restored the PSD-induced downregulation of ALK5. Furthermore, the beneficial effects of ta-VNS-including the amelioration of depressive-like behaviors, provision of neuroprotection, upregulation of serotonin (5-HT) and dopamine (DA) expression, promotion of neurogenesis, and enhancement of neuroplasticity-were all abolished upon ALK5 knockdown. Finally, ta-VNS was found to activate the Smad2/3/Gadd45β signaling pathway in an ALK5-dependent manner. Conclusion: Our findings demonstrate that ta-VNS ameliorates depressive-like behaviors and enhances neuroplasticity in PSD by activating the ALK5/Smad2/3/Gadd45β signaling pathway in the PFC. These results elucidate a novel molecular mechanism underlying the therapeutic effects of ta-VNS, highlighting its potential as a treatment strategy for PSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.